Focus Point Holdings Berhad Valuation
Is FOCUSP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FOCUSP?
Other financial metrics that can be useful for relative valuation.
|What is FOCUSP's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does FOCUSP's PE Ratio compare to its peers?
|Company||PE||Estimated Growth||Market Cap|
CENGILD Cengild Medical Berhad
KPJ KPJ Healthcare Berhad
OPTIMAX Optimax Holdings Berhad
MHCARE Metro Healthcare Berhad
FOCUSP Focus Point Holdings Berhad
Price-To-Earnings vs Peers: FOCUSP is good value based on its Price-To-Earnings Ratio (7.1x) compared to the peer average (36.5x).
Price to Earnings Ratio vs Industry
How does FOCUSP's PE Ratio compare vs other companies in the Asian Healthcare Industry?
Price to Earnings Ratio vs Fair Ratio
What is FOCUSP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||7.1x|
|Fair PE Ratio||8.7x|
Price-To-Earnings vs Fair Ratio: FOCUSP is good value based on its Price-To-Earnings Ratio (7.1x) compared to the estimated Fair Price-To-Earnings Ratio (8.7x).
Share Price vs Fair Value
What is the Fair Price of FOCUSP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: FOCUSP (MYR0.75) is trading below our estimate of fair value (MYR3.23)
Significantly Below Fair Value: FOCUSP is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
|Date||Share Price||Average 1Y Price Target||Dispersion||High||Low||1Y Actual price||Analysts|
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.